Prognostic Value of EMT-inducing Transcription Factors (EMT-TFs) in Metastatic Breast Cancer: A Systematic Review and Meta-analysis

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Imani, Saber ^a,b   Hosseinifard, Hossein ^c   Cheng, Jingliang ^a   Wei, Chunli ^a,d   Fu, Junjiang ^a,d  

^a SOUTHWEST MEDICAL UNIVERSITY   (China)

^b BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d MACAU UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Macao)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SNAIL; TWIST RELATED PROTEIN 1;

BREAST TUMOR; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION; HUMAN; META ANALYSIS; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROGNOSIS;

BREAST NEOPLASMS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PROGNOSIS; SNAIL FAMILY TRANSCRIPTION FACTORS; TRANSCRIPTION FACTORS; TWIST-RELATED PROTEIN 1;

EID: 84975708787     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep28587     Document Type: Article

References (64)

1. Tevaarwerk, A. J. et al. Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: little evidence of improvement over the past 30 years. Cancer 119, 1140-1148, doi: 10.1002/cncr.27819 (2013).
2. Gupta, G. P. & Massague, J. Cancer metastasis: building a framework. Cell 127, 679-695, doi: 10.1016/j.cell.2006.11.001 (2006).
3. Khan, M. I. et al. YB-1 expression promotes epithelial-to-mesenchymal transition in prostate cancer that is inhibited by a small molecule fisetin. Oncotarget 5, 2462-2474 (2014).
4. Chaffer, C. L. & Weinberg, R. A. A perspective on cancer cell metastasis. Science 331, 1559-1564, doi: 10.1126/science.1203543 (2011).
5. Kang, Y. & Massague, J. Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 118, 277-279, doi: 10.1016/j. cell.2004.07.011 (2004).
6. Tania, M., Khan, M. A. & Fu, J. Epithelial to mesenchymal transition inducing transcription factors and metastatic cancer. Tumour Biol 35, 7335-7342, doi: 10.1007/s13277-014-2163-y (2014).
7. Khan, M. A. et al. Thymoquinone inhibits cancer metastasis by downregulating TWIST1 expression to reduce epithelial to mesenchymal transition. Oncotarget 6, 19580-19591, doi: 10.18632/oncotarget.3973 (2015).
8. Hosono, S. et al. Expression of Twist increases the risk for recurrence and for poor survival in epithelial ovarian carcinoma patients. Br J Cancer 96, 314-320, doi: 10.1038/sj.bjc.6603533 (2007).
9. Kotiyal, S. & Bhattacharya, S. Breast cancer stem cells, EMT and therapeutic targets. Biochem Biophys Res Commun 453, 112-116, doi: 10.1016/j.bbrc.2014.09.069 (2014).
10. Dezso, Z. et al. Gene expression profiling reveals epithelial mesenchymal transition (EMT) genes can selectively differentiate eribulin sensitive breast cancer cells. PLoS One 9, e106131, doi: 10.1371/journal.pone.0106131 (2014).
11. Krasnapolski, M. A., Todaro, L. B. & de Kier Joffe, E. B. Is the epithelial-to-mesenchymal transition clinically relevant for the cancer patient? Curr Pharm Biotechnol 12, 1891-1899 (2011).
12. Peinado, H., Olmeda, D. & Cano, A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer 7, 415-428, doi: 10.1038/nrc2131 (2007).
13. Fu, J. et al. TWIST represses estrogen receptor-alpha expression by recruiting the NuRD protein complex in breast cancer cells. Int J Biol Sci 8, 522-532, doi: 10.7150/ijbs.4164 (2012).
14. Khan, M. A., Chen, H. C., Zhang, D. & Fu, J. Twist: a molecular target in cancer therapeutics. Tumour Biol 34, 2497-2506, doi: 10.1007/s13277-013-1002-x (2013).
15. Shin, N. R. et al. Overexpression of Snail is associated with lymph node metastasis and poor prognosis in patients with gastric cancer. BMC Cancer 12, 521, doi: 10.1186/1471-2407-12-521 (2012).
16. Cheng, C. W. et al. Prognostic significance of cyclin D1, beta-catenin, and MTA1 in patients with invasive ductal carcinoma of the breast. Ann Surg Oncol 19, 4129-4139, doi: 10.1245/s10434-012-2541-x (2012).
17. Zhang, D. P., Li, X. W. & Lang, J. H. Prognostic Value of beta-catenin Expression in Breast Cancer Patients: a Meta-analysis. Asian Pac J Cancer Prev 16, 5625-5633 (2015).
18. Wushou, A., Hou, J., Zhao, Y. J. & Shao, Z. M. Twist-1 up-regulation in carcinoma correlates to poor survival. Int J Mol Sci 15, 21621-21630, doi: 10.3390/ijms151221621 (2014).
19. van Nes, J. G. et al. Co-expression of SNAIL and TWIST determines prognosis in estrogen receptor-positive early breast cancer patients. Breast Cancer Res Treat 133, 49-59, doi: 10.1007/s10549-011-1684-y (2012).
20. Vesuna, F., van Diest, P., Chen, J. H. & Raman, V. Twist is a transcriptional repressor of E-cadherin gene expression in breast cancer. Biochem Biophys Res Commun 367, 235-241, doi: 10.1016/j.bbrc.2007.11.151 (2008).
21. Montserrat, N. et al. Repression of E-cadherin by SNAIL, ZEB1, and TWIST in invasive ductal carcinomas of the breast: a cooperative effort? Hum Pathol 42, 103-110, doi: 10.1016/j.humpath.2010.05.019 (2011).
22. Watanabe, O. et al. Expression of twist and wnt in human breast cancer. Anticancer Res 24, 3851-3856 (2004).
23. Yang, Z. et al. Combined Runx2 and Snail overexpression is associated with a poor prognosis in breast cancer. Tumour Biol 36, 4565-4573, doi: 10.1007/s13277-015-3101-3 (2015).
24. Joensuu, K. et al. Bmi-1, c-myc, and Snail expression in primary breast cancers and their metastases-elevated Bmi-1 expression in late breast cancer relapses. Virchows Arch 459, 31-39, doi: 10.1007/s00428-011-1096-8 (2011).
25. Muenst, S. et al. Nuclear expression of snail is an independent negative prognostic factor in human breast cancer. Dis Markers 35, 337-344, doi: 10.1155/2013/902042 (2013).
26. Zhang, A. et al. Reduced expression of Snail decreases breast cancer cell motility by downregulating the expression and inhibiting the activity of RhoA GTPase. Oncol Lett 6, 339-346, doi: 10.3892/ol.2013.1385 (2013).
27. Mimoto, R. et al. DYRK2 controls the epithelial-mesenchymal transition in breast cancer by degrading Snail. Cancer Lett 339, 214-225, doi: 10.1016/j.canlet.2013.06.005 (2013).
28. Arima, Y. et al. Induction of ZEB proteins by inactivation of RB protein is key determinant of mesenchymal phenotype of breast cancer. J Biol Chem 287, 7896-7906, doi: 10.1074/jbc.M111.313759 (2012).
29. Liu, T. et al. Dysregulated expression of Slug, vimentin, and E-cadherin correlates with poor clinical outcome in patients with basallike breast cancer. J Surg Oncol 107, 188-194, doi: 10.1002/jso.23240 (2013).
30. Wu, Z. Q. et al. Canonical Wnt signaling regulates Slug activity and links epithelial-mesenchymal transition with epigenetic Breast Cancer 1, Early Onset (BRCA1) repression. Proc Natl Acad Sci USA 109, 16654-16659, doi: 10.1073/pnas.1205822109 (2012).
31. Lundgren, K., Nordenskjold, B. & Landberg, G. Hypoxia, Snail and incomplete epithelial-mesenchymal transition in breast cancer. Br J Cancer 101, 1769-1781, doi: 10.1038/sj.bjc.6605369 (2009).
32. Gradishar, W. J. et al. Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 14, 324-354 (2016).
33. Tobias, A. Assessing the influence of a single study in the meta-analysis estimate. Stata Techn Bull 8, 15-17 (1999).
34. Kyo, S. et al. High Twist expression is involved in infiltrative endometrial cancer and affects patient survival. Hum Pathol 37, 431-438, doi: 10.1016/j.humpath.2005.12.021 (2006).
35. Lee, K. W. et al. Twist1 is an independent prognostic factor of esophageal squamous cell carcinoma and associated with its epithelialmesenchymal transition. Ann Surg Oncol 19, 326-335, doi: 10.1245/s10434-011-1867-0 (2012).
36. Wushou, A. et al. Correlation of increased twist with lymph node metastasis in patients with oral squamous cell carcinoma. J Oral Maxillofac Surg 70, 1473-1479, doi: 10.1016/j.joms.2011.06.212 (2012).
37. Zhang, J. et al. Slug is a key mediator of hypoxia induced cadherin switch in HNSCC: correlations with poor prognosis. Oral Oncol 49, 1043-1050, doi: 10.1016/j.oraloncology.2013.08.003 (2013).
38. Lemma, S. et al. Biological roles and prognostic values of the epithelial-mesenchymal transition-mediating transcription factors Twist, ZEB1 and Slug in diffuse large B-cell lymphoma. Histopathology 62, 326-333, doi: 10.1111/his.12000 (2013).
39. Zhang, P. et al. Prognostic role of Twist or Snail in various carcinomas: a systematic review and meta-analysis. Eur J Clin Invest 44, 1072-1094, doi: 10.1111/eci.12343 (2014).
40. Zeng, J. et al. Prognostic value of Twist in lung cancer: systematic review and meta-analysis. Transl Lung Cancer Res 4, 236-241, doi: 10.3978/j.issn.2218-6751.2015.04.06 (2015).
41. Zhang, Y. Q. et al. Over-Expressed Twist Associates with Markers of Epithelial Mesenchymal Transition and Predicts Poor Prognosis in Breast Cancers via ERK and Akt Activation. PLoS One 10, e0135851, doi: 10.1371/journal.pone.0135851 (2015).
42. Ito, M. et al. Evaluation of aldehyde dehydrogenase 1 and transcription factors in both primary breast cancer and axillary lymph node metastases as a prognostic factor. Breast Cancer, doi: 10.1007/s12282-015-0583-1 (2015).
43. Soini, Y. et al. Transcription factors zeb1, twist and snai1 in breast carcinoma. BMC Cancer 11, 73, doi: 10.1186/1471-2407-11-73 (2011).
44. Ishigaki, Y. et al. Scanning electron microscopy with an ionic liquid reveals the loss of mitotic protrusions of cells during the epithelial-mesenchymal transition. Microsc Res Tech 74, 1024-1031, doi: 10.1002/jemt.20989 (2011).
45. Cheng, C. W. et al. Mechanisms of inactivation of E-cadherin in breast carcinoma: modification of the two-hit hypothesis of tumor suppressor gene. Oncogene 20, 3814-3823, doi: 10.1038/sj.onc.1204505 (2001).
46. Peinado, H., Ballestar, E., Esteller, M. & Cano, A. Snail mediates E-cadherin repression by the recruitment of the Sin3A/histone deacetylase 1 (HDAC1)/HDAC2 complex. Mol Cell Biol 24, 306-319 (2004).
47. Fu, J. et al. The TWIST/Mi2/NuRD protein complex and its essential role in cancer metastasis. Cell Res 21, 275-289, doi: 10.1038/cr.2010.118 (2011).
48. Denslow, S. A. & Wade, P. A. The human Mi-2/NuRD complex and gene regulation. Oncogene 26, 5433-5438, doi: 10.1038/sj.onc.1210611 (2007).
49. Guschin, D., Wade, P. A., Kikyo, N. & Wolffe, A. P. ATP-Dependent histone octamer mobilization and histone deacetylation mediated by the Mi-2 chromatin remodeling complex. Biochemistry 39, 5238-5245 (2000).
50. Fu, J. et al. Deleted in breast cancer 1, a novel androgen receptor (AR) coactivator that promotes AR DNA-binding activity. J Biol Chem 284, 6832-6840, doi: 10.1074/jbc.M808988200 (2009).
51. Zhang, L. et al. DLX4 upregulates TWIST and enhances tumor migration, invasion and metastasis. Int J Biol Sci 8, 1178-1187, doi: 10.7150/ijbs.4458 (2012).
52. Vesuna, F. et al. Twist contributes to hormone resistance in breast cancer by downregulating estrogen receptor-alpha. Oncogene 31, 3223-3234, doi: 10.1038/onc.2011.483 (2012).
53. Qin, Q. et al. Normal and disease-related biological functions of Twist1 and underlying molecular mechanisms. Cell Res 22, 90-106, doi: 10.1038/cr.2011.144 (2012).
54. Zhuo, X. et al. Expression and clinical significance of microvessel density and its association with TWIST in nasopharyngeal carcinoma. Int J Clin Exp Med 8, 1265-1270 (2015).
55. Che, N. et al. The role of Twist1 in hepatocellular carcinoma angiogenesis: a clinical study. Hum Pathol 42, 840-847, doi: 10.1016/j. humpath.2010.03.010 (2011).
56. Wang, Y. et al. Benzo(a)pyrene promotes A549 cell migration and invasion through up-regulating Twist. Arch Toxicol 89, 451-458, doi: 10.1007/s00204-014-1269-8 (2015).
57. Lv, Q. et al. Prognostic value of circulating tumor cells in metastatic breast cancer: a systemic review and meta-analysis. Clin Transl Oncol 18, 322-330, doi: 10.1007/s12094-015-1372-1 (2016).
58. Liang, F. et al. The prognostic value of tumor budding in invasive breast cancer. Pathol Res Pract 209, 269-275, doi: 10.1016/j. prp.2013.01.009 (2013).
59. Richardson, W. S., Wilson, M. C., Nishikawa, J. & Hayward, R. S. The well-built clinical question: a key to evidence-based decisions. ACP J Club 123, A12-13 (1995).
60. Higgins, J. P. & Thompson, S. G. Quantifying heterogeneity in a meta-analysis. Stat Med 21, 1539-1558, doi: 10.1002/sim.1186 (2002).
61. Tierney, J. F. et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8, 16, doi: 10.1186/1745-6215-8-16 (2007).
62. Munafo, M. R., Clark, T. G. & Flint, J. Assessing publication bias in genetic association studies: evidence from a recent meta-analysis. Psychiatry Res 129, 39-44, doi: 10.1016/j.psychres.2004.06.011 (2004).
63. Egger, M., Davey Smith, G., Schneider, M. & Minder, C. Bias in meta-analysis detected by a simple, graphical test. BMJ 315, 629-634 (1997).
64. Higgins, J. P., Thompson, S. G., Deeks, J. J. & Altman, D. G. Measuring inconsistency in meta-analyses. BMJ 327, 557-560, doi: 10.1136/bmj.327.7414.557 (2003).